Abecma cuts worse outcomes risk in half in hard-to-treat myeloma cases
Abecma (idecabtagene vicleucel or ide-cel) reduced the risk of disease progression or death by half in adults with relapsed or refractory multiple myeloma (RRMM) who’d received two to four therapies without responding to the last one. That’s according to full results of the Phase 3 KarMMa-3 clinical…